FREE WEBINARS
The Journey to Generic Oncology
Speakers:
Grace Guo
Senior Technical Specialist, Phenomenex
Grace Guo graduated from Johns Hopkins University with a Master’s degree in Material Science and Engineering. She joined Phenomenex Technical Team in 2017, providing technical support globally. With more than 9 years of experience in SPE, HPLC, and GC, she delivered 90+ seminars and webinars globally covering food and environmental, clinical, pharma, and biopharma industries.
One webinar, two viewing options
We know you're busy, select a viewing session that works best for you.
Viewing Options
Session 1
Tuesday, October 20, 2026
Los Angeles: 10:00 AM PT | New York: 1:00 PM EST
Mexico City: 12:00 PM CDT
Session 2
Wednesday, October 21, 2026
London: 9:00 AM BST | Berlin: 10:00 AM CEST
Mumbai: 1:30 PM IST
Overview
As more oncology therapies transition from innovative medicines to widely available generic treatments, analytical laboratories play a critical role in ensuring these medicines remain safe, effective and accessible to patients. This webinar highlights a range of oncology applications, including olaparib, sorafenib, imatinib, ibrutinib, and the combination of palbociclib and letrozole, demonstrating how modern HPLC methods and alternative column technologies can support assay and impurity analysis while meeting compendial and quality requirements. Attendees will gain practical insights into method modernisation, column selection and analytical strategies that help manufacturers efficiently bring high-quality generic oncology medicines to market.
Key Learning Points
- Understand the role of robust analytical testing in supporting the quality, safety, and wider availability of generic oncology medicines.
- Learn how alternative HPLC columns and modern chromatographic approaches can be applied to oncology drug assays and impurity methods while maintaining compliance and system suitability requirements.
- Explore analytical challenges and solutions across a range of oncology therapies, including olaparib, sorafenib, imatinib, ibrutinib, palbociclib and letrozole.
- Discover opportunities to improve laboratory efficiency, method robustness and throughput without compromising analytical performance.
Who Should Attend
Any lab managers, bench chemists, and QA/AC analysts who work with USP/Ph. Eur. monographs for oncology therapies or other pharmaceuticals.
Select a time slot that works best for you:
By submitting your information, you agree that Phenomenex may collect and further process your personal data in accordance with its Privacy Policy.
You may object to receiving further information at any time.
